As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

Drug developers can now leverage large language models to draft regulatory documents, which they hope will shorten the time ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

MIT engineers have devised a new way to deliver certain drugs in higher doses with less pain, by injecting them as a ...

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

CERo Therapeutics (CERO) announces that the Company has received clearance by the U.S. Food and Drug Administration, FDA, for a second ...